



Innovations that work.™

ACN 109 200 900

ASX ANNOUNCEMENT

31 July 2026

JUNE 2026 QUARTERLY ACTIVITIES REPORT

Eden Innovations Ltd (ASX:EDE) ("Eden" or "the Company") is pleased to provide the following activities report for the quarter ended 30 June 2026.

HIGHLIGHTS

Strong EdenCrete® Trial results and Regional Expansion:

- A long-term developed pipeline of encouraging trial results has started to bear fruit. Eden has during the last year seen exponential growth in number of EdenCrete® dosage system installations, especially from an unusual fast acceptance of EdenCrete® Pz7 by the RMC industry. It is expected the volume of EdenCrete® products sold will start growing in similar fashion in the near future, as the installations allow RMC plants to faster and more easily implement the EdenCrete® products in their portfolio of mix designs.
- Long term trial success with the Amrize group in Texas and Minnesota resulted in first EdenCrete® Pz7 installations in those states this quarter, along with further plant and mix design expansion with Amrize in Canada.
- Encouraging trial results continue to build the pipeline for future EdenCrete® volume growth. This quarter EdenCrete® Pz/Pz7 trials in the Delhi area with independent ready-mix concrete companies, high-rise property developers, and a leading Indian Government agency (CRRI) have been particularly encouraging.
- Eden will be increasing staff count for on-the-ground concrete knowledge and customer support in the US and India to assist the expected rise in EdenCrete® demand.

EdenShield® Expansion:

- Ms Julie Bown appointed as Strategic Advisor – Defence (April 2026), bringing more than 30 years' experience in the defence and aerospace sectors with global defence primes Thales and Raytheon (in Australia), to progress commercialisation pathways for EdenShield® products.
- Antanas Guoga (Tony G), a former Member of the European Parliament, appointed as Head of EdenShield® (Europe) (May 2026) to spearhead European operations and growth, including government off-takes, EU & NATO procurement, strategic partnerships and joint ventures.

OptiBlend® US Momentum: Continued order intake from range of customers including US data centre operators; US\$2.90 million of OptiBlend® quotations issued during FY26 (45 quotations), including US\$1.10 million in June 2026 alone.

\$4.05 Million Placement Completed: Institution-led placement at \$0.18 per share to raise \$4.05 million (before costs) completed, cornerstoned by L1 Capital Global Opportunities Master Fund.

Debt Free Status: Shareholders approved the settlement of remaining shareholder loans and accrued director fees at the General Meeting held on 24 July 2026, with the settlement shares to be issued in the coming days, completing the Company's balance sheet reconstruction.

Outlook: Eden enters FY2027 well-funded, with \$5.2 million cash at bank at 30 June 2026, to accelerate commercialisation of its EdenCrete®, OptiBlend® and EdenShield® technology lines across the Americas, Europe and India.


SALES AND ACTIVITIES DURING Q4 FY26

EdenCrete® Products Highlights

Ready Mix Concrete Plant Growth and North American Expansion

During the quarter, Eden US continued the roll-out of EdenCrete® Pz7 bulk storage tank and dispensing equipment installations across the Amrize and Quikrete ready-mix concrete (“RMC”) plant networks in North America, following the significant expansion reported in the March 2026 quarter. Subsequent to quarter-end, Amrize requested Eden US install a further four EdenCrete® Pz7 bulk storage and automated dispensing systems at three additional plant locations: a double-plant site in Texas and a further plant in Minnesota (extending Eden’s US footprint into these new US states), and a second plant in the greater Toronto area, Canada, in response to growing demand for EdenCrete® Pz7-enriched concrete mixes in the Canadian market.

Each new installation is accompanied by orders for starter volumes of EdenCrete® Pz7 totalling approximately US\$32,000 (approx. A\$45,750) and significantly expands the targeted volume of concrete in high-growth areas of North America.



South America and International Markets

Eden US has been supplying EdenCrete® Pz7 to enrich standard low-carbon concrete mixes at nine Holcim plants in Ecuador since 2024. Total cumulative purchases from Holcim Ecuador exceed US\$697,830.

Holcim has also commenced rolling out EdenCrete® Pz7 dispensing systems at plants owned by its subsidiaries in the US and Ecuador, while continuing extended trials of EdenCrete® Pz and EdenCrete® Pz7 in Canada, Mexico, the UK, and France. In India, the Company’s subsidiary, Eden India, received strong results during the quarter from a suite of EdenCrete® trials being undertaken in the Delhi area — see Indian EdenCrete® Trials section.

EdenShield® Division Expansion

Following the launch during the March quarter of EdenShield® — Eden's dedicated defence, military and critical infrastructure division, formed to commercialise the Company's product suite across critical infrastructure and national security applications — Eden made two key appointments during the quarter to drive EdenShield®'s growth in Australia and Europe.

In April 2026, **Eden appointed Ms Julie Bown as Strategic Advisor – Defence**. Ms Bown is a highly experienced senior executive with more than 30 years' experience across the defence and aerospace sectors, having held senior leadership roles with global defence primes Thales and Raytheon (in Australia), with responsibility for large-scale, multi-site operations and the delivery of complex, mission-critical capabilities across advanced manufacturing, base operations, sustainment and systems integration. She brings deep relationships across the Australian defence ecosystem, supported by international experience working in the United States, United Kingdom and Europe.

Ms Bown will provide strategic advice to the Board and management team to support engagement with Defence and government stakeholders, alignment of Eden's technologies to operational requirements, and progression of commercialisation pathways for EdenShield® products. This initiative is aligned with the Australian Government's National Defence Strategy and Integrated Investment Program.

Head of EdenShield® (Europe) Appointed

In May 2026, **Eden appointed Antanas Guoga as Head of EdenShield® (Europe)**. Mr Guoga is responsible for spearheading the growth and development of EdenShield®'s European operations, including sourcing, negotiating and securing government off-take agreements, engaging with major European defence contractors, managing EU & NATO procurement (including exploring potential EU Defence Fund grants), strategic partnerships, major infrastructure developments, joint ventures and other defence and military contracts.

Mr Guoga is a former Member of the European Parliament with an extensive network across European business, government, infrastructure, defence and military sectors, and is a prominent global technology investor and entrepreneur with a successful track record of building technology businesses internationally. His appointment is a key catalyst for Eden to commercialise its EdenShield® suite of technologies across European government, military and critical infrastructure markets, at a time when European defence budgets and infrastructure resilience spending are at their highest levels in a generation. Mr Guoga's remuneration structure solely aligned with performance success, comprising (approved by shareholders at the General Meeting held on 24 July 2026) 10 million options exercisable at \$0.25, 25 million options exercisable at \$0.35 vesting in three equal tranches upon share price or European government contract milestones being met, and 5 million Performance Rights vesting upon completion of a transaction with gross revenue of a minimum \$15 million from a profitable project.

Eden India - EdenCrete® Positive Trial Results

Eden was delighted to report in June that a suite of recent important Indian trials of EdenCrete®Pz7 enriched concrete all demonstrated significant performance improvements and/or mix design cost-reduction opportunities. The trials, conducted in the Delhi area, were undertaken in parallel with multiple parties from three market sectors — independent Indian ready-mix concrete companies, high-rise property developers, and a leading Indian Government agency, the Central Road Research Institute (CRRI).

Subsequent to quarter-end, on 21 July 2026, Eden received the final study report from CRRRI covering the trials conducted at its Delhi laboratory in May 2026. The report confirmed that the EdenCrete®Pz7 enriched mixes, when compared against the same concrete mixes without EdenCrete®Pz7:-

- significantly increased abrasion resistance by up to 28%;
- reduced drying-shrinkage by up to 25% (with the greatest reduction in fly-ash mixes);
- increased compressive strength by up to 19%;
- increased flexural strength by up to 14%; and
- slightly improved the workability of paving-grade mixes.

The two grades trialled were a 40 MPa mix used for new highways and a 60 MPa mix used for “white topping” repair of worn concrete pavement.

The strength buffer generated by the addition of EdenCrete®Pz7 enables replacement of a meaningful percentage of both expensive Ordinary Portland Cement (OPC) and micro silica mix contents with much cheaper supplementary cementitious materials (SCMs) such as fly ash or slag, resulting in stronger, cheaper concrete with a significantly lower CO2 footprint. The two grades of concrete being tested with CRRRI are M60 grade concrete, used for bridge over-lay and ultra-thin white topping concrete road repairs, and M40 pavement quality concrete, regularly used in the making of new roads and pavements. Further trials with CRRRI are scheduled.

As a result of the positive results and feedback from the parties involved, Eden intends to expand its trials in the Delhi area, as well as into other Indian regions with significant high-rise construction activity, and to increase its Indian staff count to accommodate the increased interest.

Eden India intends to explore with CRRRI ways to accelerate field trials of EdenCrete® enriched concrete for new highways and white topping highway repairs. CRRRI is highly respected across Indian Federal and State Governments, and its report could assist Eden to break into the Indian infrastructure market.

India is now the second largest construction growth market in the world, closely behind China and having passed the USA, with the Indian government allocating a record ₹12.20 lakh crore (approximately USD135 billion) to infrastructure spending for FY2026–27 alone. Since 2014, India has built approximately 50,000 kms of new concrete highways and continues building approximately 4 kms of new concrete highways per day. With enormous growth projected across all Indian market sectors, Eden is confident that, if the early results are repeated when the current trials are completed, EdenCrete® products have a huge emerging market in India that could well become Eden’s largest market in the world.

OptiBlend® Highlights

Overview

OptiBlend® is Eden's patented retrofit dual-fuel technology that allows conventional diesel engines to operate primarily on natural gas — up to a 65% natural gas / 35% diesel mix — without modification to the engine or existing diesel fuel system. This reduces fuel costs, lowers CO₂ and diesel particulate emissions, and extends backup generator run-time by up to 300%.

The technology is gaining strong commercial traction with US data centre operators seeking to reduce operating costs and emissions while improving energy security.

OptiBlend® addresses a clear operational need for backup power operators — lower fuel costs, reduced emissions, and a dramatic increase in generator runtime — without requiring any modification to existing engines or diesel fuel infrastructure.

US Sales & Pipeline

During FY26, Eden US issued 45 OptiBlend® quotations totalling approximately US\$2.90 million, including 9 quotations totalling approximately US\$1.10 million issued in June 2026 alone.

For the full financial year ended 30 June 2026, total US OptiBlend® sales were US\$811k, which were approximately 33% higher than US OptiBlend® sales in FY2025 of approximately US\$609k. This result continues the year-on-year growth of the OptiBlend® business in the US market, driven in particular by demand from data centre and drilling customers. US OptiBlend® sales recorded during the June 2026 quarter totalled US\$108k.

Corporate Activities

\$4.05 Million Institution-Led Placement Completed

During the quarter, Eden completed a \$4.05 million (before costs) institution-led placement of 22.5 million fully paid ordinary shares at an issue price of \$0.18 per share, being the last traded price on the ASX at the time of the announcement and a 41% premium to the then 15-day VWAP. The Placement was cornerstoned by L1 Capital Global Opportunities Master Fund, with Oakley Capital Partners Pty Limited acting as Lead Manager and Bell Potter Securities Limited as Co-Manager.

Placement funds are being applied to accelerate expansion and new business development for EdenShield®, ongoing commercialisation of the Company's EdenCrete®, OptiBlend® and carbon nanotube products / technology platform, and working capital. Following shareholder approval at the General Meeting held on 24 July 2026, Placement participants will also be issued one free attaching option for every two Placement Shares subscribed, each exercisable at \$0.20 and expiring 15 October 2028.

Settlement of remaining loans and director fees: Following shareholder approval at the General Meeting of the Company held on 24 July 2026, the Company will complete its move to debt-free status through the issue, in the coming days, of shares to settle all outstanding loans from Arkenstone Pty Ltd and March Bells Pty Ltd and accrued director fees totalling \$1,839,141 in aggregate, at the same price as the earlier convertible loan settled in February 2026.

Funding

At 30 June 2026, the Company is well capitalised with \$5.2 million cash at bank, and no third-party debt (with remaining director loans and fees to be fully settled in shares in the coming days, following shareholder approval at the General Meeting held on 24 July 2026).

The Company also notes that it has approximately 146.3 million EDEO options on issue, which are currently in-the-money based on the ASX closing price of Company shares on 30 July 2026. If all of these options were to be exercised, this would result in an additional cash injection of up to approximately \$10.2 million to the Company. Although there is no guarantee that the Company's share price will remain above the exercise price of some or all of these option classes prior to the relevant expiry date.

Management

Dr Allan Godsk Larsen, in his new role of Managing Director is leading the Company's next phase of global growth following completion of the balance sheet restructuring program. Management continues to consider a number of further key hires, including within the business development team.

Group Outlook and Priorities

Eden's recapitalisation is complete, including repayment of all debts following approval by shareholders in July 2026 for conversion of all outstanding loans to equity, and the \$4.05 million placement completed during the quarter.

Eden enters FY2027 with a materially de-risked balance sheet and a motivated management & sales team well positioned to rapidly commercialise the EdenCrete®, OptiBlend® and EdenShield® technology lines.


Key priorities for FY2027 include:

- Expanding the Indian EdenCrete® trials in the Delhi area and other regions, and converting the positive trial results with CRR, ready mix producers and high-rise developers into commercial sales;
- Scaling EdenCrete® Pz7 sales across the Amrize, Quikrete, and Holcim ready mix plant networks in the Americas;
- Securing initial commercial engagements and pilot project opportunities for EdenShield®, including building the European opportunity pipeline under the leadership of the newly appointed Head of EdenShield® (Europe);
- Expanding OptiBlend® order flow from US data centre operators and converting the active US quotation pipeline;
- Advancing carbon nanotube concrete R&D for applications to AI and cloud data centre infrastructure;
- Progressing EdenCrete® trials and partnerships in Canada, Mexico, the UK, and France; and
- Continuing to advance towards the Group's target to reach positive operating cash flow.

Description of payments to related parties of the entity and their associates (LR 5.3.5)

The Company paid \$239k to related parties during the quarter, comprising \$133k to Dr Allan Larsen for Managing Director services and \$106k for Executive Chair and Non-executive director fees.

ENDS



Gregory H Solomon
Executive Chairman

This report was authorised by the Board of the Company.

Forward Looking Statements

Statements contained in this release, particularly those regarding possible or assumed future performance, revenue, costs, dividends, production levels or rates, prices or potential growth of the Company are, or may be, forward looking statements. Such statements relate to future events and expectations and as such, involve known and unknown risks and uncertainties. Actual results and developments may differ materially from those expressed or implied by these forward-looking statements depending on a variety of factors. The past performance of the Company is no guarantee of future performance.

None of the Company's directors, officers, employees, agents or contractors makes any representation or warranty (either express or implied) as to the accuracy or likelihood of fulfilment of any forward-looking statement, or any events or results expressed or implied in any forward-looking statement, except to the extent required by law. You are cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statements in this announcement reflect views held only as at the date of this announcement.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Eden Innovations Ltd

ABN

58 109 200 900

Quarter ended ("current quarter")

30 June 2026

Consolidated statement of cash flows		Current Quarter \$A'000	Year to Date (12 months) \$A'000
1.	Cash flows from operating activities		
1.1	Receipts from customers	238	2,075
1.2	Payments for		
	(a) research and development	-	-
	(b) product manufacturing and operating costs	(593)	(2,305)
	(c) advertising and marketing	(136)	(31)
	(d) leased assets	-	-
	(e) staff costs	(935)	(2,798)
	(f) administration and corporate costs	(490)	(1,462)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	18	30
1.5	Interest and other costs of finance paid	-	(563)
1.6	Income taxes paid (India)	-	(49)
1.7	Government grants and tax incentives	-	-
1.8	Other (provide details if material)	-	-
1.9	Net cash from / (used in) operating activities	(1,898)	(5,103)
2.	Cash flows from investing activities		
2.1	Payments to acquire or for:	-	-
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	(2)
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-

Consolidated statement of cash flows		Current Quarter \$A'000	Year to Date (12 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	7,019
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	(591)
2.6	Net cash from / (used in) investing activities	-	6,426
3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	4,000	9,163
3.2	Proceeds from issue of convertible debt securities	-	2,200
3.3	Proceeds from exercise of options	738	1,069
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(270)	(638)
3.5	Proceeds from borrowings	-	239
3.6	Repayment of borrowings	-	(8,568)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	4,468	3,465
4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	2,566	412
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(1,898)	(5,103)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	6,426
4.4	Net cash from / (used in) financing activities (item 3.10 above)	4,468	3,465
4.5	Effect of movement in exchange rates on cash held	42	(22)
4.6	Cash and cash equivalents at end of period	5,178	5,178

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current Quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	4,176	2,566
5.2	Call deposits	1,002	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	5,178	2,566

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	239
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		
Fees paid to non-executive directors and the management director as a consultant.		

7.	Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at Quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1	Loan facilities	1,230	1,230
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	Total financing facilities	1,230	1,230
7.5	Unused financing facilities available at quarter end		-
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well. At call, unsecured loan from Arkenstone Pty Ltd and March Bells Pty Ltd accruing interest at 9.97% pa. These loans will be substantially repaid through the issue of shares following approval by shareholders at general meeting held on 24 July 2026.		

8.	Estimated cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	(1,898)
8.2	Cash and cash equivalents at quarter end (item 4.6)	5,178
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	5,178
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	2.7
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>		
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1	Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
	N/A	
8.6.2	Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
	N/A	
8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
	N/A	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>		

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 31 July 2026

Authorised by: Brett Tucker, Company Secretary
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.